LY2835219 free base

LY2835219 free base

Catalog Number:
L002368739APE
Mfr. No.:
APE-A3575
Price:
$196
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

      • Properties
        • Alternative Name
          CDK4/6 dual inhibitor;LY 2835219 (free base);LY-2835219 (free base); N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine
          CAS Number
          1231929-97-7
          Molecular Formula
          C27H32F2N8
          Molecular Weight
          506.59
          Appearance
          A solid
          Purity
          98.00%
          Solubility
          insoluble in H2O; ≥4.83 mg/mL in DMSO with gentle warming and ultrasonic; ≥6.34 mg/mL in EtOH with gentle warming
          Storage
          Store at -20°C

          * For Research Use Only

    We Also Recommend

    LY341495

    $388

    Matrine

    $417

    Matrine

    $180

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.